Skip to main content
. 2017 Jun 22;14(2):2531–2536. doi: 10.3892/ol.2017.6459

Figure 2.

Figure 2.

Comparison of MP levels of patients with Philadelphia chromosome-negative myeloproliferative neoplasms, with and without (A) splenomegaly or (B) thrombosis. *P<0.05. MPs, microparticles; EMPs, endothelial MPs; PMPs, platelet-derived MPs; RMPs, red blood cell MPs; TF+MPs, tissue factor-positive MPs.